Schizophrenia Flashcards

(57 cards)

1
Q

What is the estimated prevalence of schizophrenia?

A

The estimated prevalence is 1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the mean duration of schizophrenia?

A

The mean duration is 15 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does schizophrenia affect basic human processes?

A

Schizophrenia affects the most basic human processes of perception, emotion, and judgment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why is SCZ called a heterogeneous syndrome?

A

It has no single defining symptom or sign. It is considered a ‘spectrum of disease states’ grouped under one umbrella term.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is schizophrenia diagnosed?

A

SCZ cannot be identified with a diagnostic laboratory test. Diagnosis is based on observing psychotic phenomena (hallucinations, delusions, and thought disorder) after other causes of psychosis (such as affective disorder or delirium) have been excluded. It is also based on operational criteria defined in manuals like DSM-V or ICD-11, considering positive, negative, and cognitive symptoms. PANS scale remains the gold standard for evaluating the effect of antipsychotics on SCZ in both clinical and research setting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the age of onset for schizophrenia?

A

Onset typically occurs in late teens to early 20s, often presenting as a first psychotic episode. Onset typically occurs in adolescence or early adulthood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the life course of schizophrenia?

A

It is a lifelong course of illness with exacerbations, remissions, substantial residual symptoms, and functional impairment. The outcome can range from complete recovery to chronic need of care.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the three main categories of symptoms in schizophrenia?

A

Symptoms fall into three main categories: positive symptoms, negative symptoms, and cognitive symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe positive symptoms.

A

Positive symptoms are characterised by abnormal thoughts, perceptions, language, and behaviour. They represent a gain of function or mental phenomena that do not occur in healthy people. They essentially cover symptoms related to recurrent psychosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List examples of positive symptoms.

A

Examples include delusions, hallucinations (including auditory and visual hallucinations), disorganized thinking/speech, disorganised behaviour, and lack of insight (unawareness that delusions/hallucinations aren’t real). Individuals with schizophrenia are more likely to have persecutory delusions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe negative symptoms.

A

Negative symptoms are characterised by restrictions in the range and intensity of emotional expression, communication, body language, and interest in normal activities. They represent a loss of function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List examples of negative symptoms.

A

Examples include blunted (flat) affect, alogia (reduced speech, curt and detached responses, less fluid speech), avolition (lacking motivation, spontaneity, initiative, e.g., sitting for long periods, ceasing participation in activities), and anhedonia (lacking pleasure or interest in enjoyable activities).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe cognitive symptoms.

A

Subtle cognitive problems are increasingly recognised as a central feature of schizophrenia. Individuals often present with cognitive dysfunction long before diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List examples of cognitive symptoms.

A

Examples include impairments in attention, working memory, learning, verbal fluency, motor speed, and executive functions. Cognitive deficits remain relatively stable and are apparent even in first-episode patients. These deficits lead to impairment of skills and diminished functional capacity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is poor working memory associated with?

A

Poor working memory is linked to dysfunction of the dorsolateral pre-frontal cortex, and even patients with good performance are inefficient in using prefrontal networks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Are all symptoms equally treatable with pharmacological intervention?

A

No, positive symptoms are generally best treated by pharmacological intervention, followed by negative symptoms, and then cognitive symptoms. There is a significant unmet need for the pharmacological treatment of cognitive symptoms. Cognitive deficits seem to remain after treatment and are difficult to treat pharmacologically.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What factors contribute to the onset of schizophrenia?

A

Both environmental and genetic factors play a role in the onset of schizophrenia. It is suggested to be an accumulation of events rather than a single cause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What environmental factors are linked to schizophrenia?

A

Environmental factors include urban populations being more affected than rural populations, obstetric complications (premature birth, low birth weight, pre-eclampsia, resuscitation at birth), prenatal nutritional deficiency, seasonal influences of birth month (small increase in winter months), and drug use.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Is there a genetic component to schizophrenia?

A

Yes, schizophrenia is more common in relatives of those with the disorder, suggesting a genetic component. For example, MZ twins of affected individuals have an increased risk of ~50%. Aspects of cognitive impairment may be under genetic control.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the two main neurotransmitter systems implicated in schizophrenia?

A

The two main transmitter systems implicated are Dopamine and Glutamate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the “dopamine hypothesis” of schizophrenia?

A

The dopamine hypothesis suggests that schizophrenia arises from DA hyperfunction. It proposes that an excess of dopamine signalling, particularly in midbrain pathways projecting to the striatum, drives psychosis. The hypothesis derived in part from the discovery of antipsychotics in the 1950s.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What evidence supports the dopamine hypothesis?

A

Evidence includes:
▪Amphetamine or L-Dopa administration can mimic symptoms of SCZ.
▪Antipsychotic drugs alleviate some symptoms of amphetamine psychosis.
▪Excess DA release occurs in SCZ. Neurochemical imaging studies show abnormalities in DA synthesis and release, with meta-analyses concluding an increased presynaptic capacity of DA neurons to synthesise and release DA.
▪Increased DA receptor binding, specifically D2 receptors, is seen in patient brains and scans. Individuals with SCZ have more D2 receptor occupancy in the striatum.
▪Genetic evidence, such as variation in loci for the D2 receptor, supports the hypothesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How does the aberrant salience hypothesis explain the link between dopamine and psychotic symptoms?

A

This hypothesis suggests that DA dysregulation in the dorsal striatum causes irrelevant environmental stimuli to become salient (losing correct signal to noise balance), forming the basis of delusion formation. A feedback loop is suggested where environmental/genetic factors contribute to a sensitised DA system, priming psychotic episodes, and cognitive schemas are impacted by aberrant DA levels, leading to biased sensory perception and further potentiated DA release, potentially tipping individuals over a threshold into psychosis.

24
Q

What is the perceptual expectations hypothesis?

A

An alternative mechanism suggests that DA dysfunction leads to false associations and misperceptions because too much DA alters the threshold for what is inferred to be important in internal representations.

25
How is the dopamine hypothesis tested in animal models?
Mice models have been developed to quantify this phenomenon. Studies show a correlation between increased DA (e.g., via artificial optogenetic release) and the number of high-confidence false alarms (akin to hallucinations). This effect can be blocked by antipsychotics like haloperidol.
26
What is the glutamate hypothesis of SCZ?
The glutamate hypothesis proposes decreased glutamatergic signalling via NMDA receptors (NMDAR hypofunction).
27
What evidence supports the glutamate hypothesis?
Evidence includes: ▪NMDA receptor antagonists (PCP, ketamine) can cause psychotic and cognitive abnormalities reminiscent of SCZ. These are psychomimetic drugs. ▪Infusion of brain-permeable NMDAR autoantibodies can mimic psychotic symptoms. ▪NMDA receptor agonists (e.g., D-serine, glycine, sarcosine) improve symptoms and have therapeutic benefit. ▪Reduced NMDA receptor expression in mouse models displays SCZ-like symptoms. ▪Genetic evidence, such as variations in loci coding for Glu receptors, supports the hypothesis. Rare penetrant variants in the GRIN2A subunit (part of the NMDAR) lead to significantly increased risk, likely due to haploinsufficiency and less NMDA receptor protein at the synapse, causing NMDAR hypofunction. ▪Heterozygous mouse mutants of GRIN2A can be used to model SCZ, showing PFC hypoactivity, hippocampal hyperactivity, and a hyperdopaminergic state in the striatum, suggesting a link between Glu hypofunction and DA dysregulation.
28
How might NMDAR hypofunction relate to disrupted inhibition (GABA) in SCZ?
Post-mortem studies show altered staining for GABA metabolism components. NMDARs on interneurons monitor excitatory tone; in their absence, interneurons are less able to detect excitability and homeostatically compensate by decreasing inhibition (reduced GABA synthesis). NMDA hypofunction leads to decreased GAD and decreased GABA release, disrupting the E/I balance. Chronic NMDAR antagonist administration can induce similar changes that preferentially diminish interneuron activity.
29
How might disrupted E/I balance relate to cognitive symptoms?
Disrupted E/I balance can disrupt gamma oscillations, leading to working memory impairments.
30
How might the glutamate and dopamine hypotheses be integrated?
An integrated model suggests that lower cortical Glu leads to less activation of GABA interneurons, resulting in lower cortical GABA levels and disrupted E/I balance. This causes lower inhibition of cortical Glu neurons projecting to the basal ganglia, leading to disinhibition of striatal DA neurons and increased DA release in the striatum. This provides evidence of a link between Glu hypofunction and a hyperdopaminergic state.
31
What are the changes in brain structure in schizophrenia?
Ventricular enlargement (lateral and third ventricles), and medial temporal lobe volume reduction (hippocampal formation, subiculum, parahippocampal gyrus). There is also a reduction in grey matter, cortical volume, and overall brain size/weight.
32
Are structural changes always progressive?
Some sources suggest structural changes may be progressive, but this remains controversial. Changes are relatively static post-presentation, though some subgroups display disease progression.
33
Is there evidence of neurodegenerative disease features in SCZ?
No cell death is observed, and there is no evidence of features of neurodegenerative diseases such as inclusion bodies, plaques, or reactive gliosis.
34
What does the "reduced neuropil hypothesis" suggest?
This hypothesis suggests evidence of synaptic deficits. It describes a reduction of neuropil, reduced pyramidal neuron cell body size, reduced dendritic arborisations, spine density, and synaptic connectivity.
35
What is the evidence for synaptic density changes?
A loss of dendritic spines/decreased density of postsynaptic elements has been concluded from post-mortem meta-analysis. PET imaging studies using the drug 11C-UCB-J have provided evidence of reduced synaptic density in the brains of living patients. Postmortem and in-vivo studies show a decreased number of synapses, particularly in frontal brain regions.
36
How do structural changes relate to symptom severity?
Individuals with more pronounced structural changes tend to have a more severe presentation.
37
When do neurological changes occur relative to symptom onset?
Neurological changes, such as cortical shrinkage, precede the first presentation of disease. They occur during the prodromal phase in individuals who subsequently develop the full manifestation of SCZ.
38
How are first-generation antipsychotics thought to work?
1st-generation antipsychotics (e.g., chlorpromazine, haloperidol, perphenazine) are thought to work by blocking DA signalling. Their potency in treating positive symptoms is strongly correlated with their affinity for D2 receptors. They primarily work by blocking D2 receptors in the striatum.
39
What are some side effects of first-generation antipsychotics?
They can cause extrapyramidal side effects (EPS) such as tremor, rigidity, dystonia, and tardive dyskinesia. These side effects are related to the nigrostriatal DA system.
40
How do second-generation (atypical) antipsychotics differ?
2nd generation antipsychotics (e.g., risperidone, clozapine) are less likely to cause EPS. They tend to also act on serotonin receptors (e.g., clozapine targets 5HT2A receptors).
41
When is clozapine used?
Clozapine can be used in treatment-resistant individuals. It has less EPS but other serious side effects.
42
How does Xanomeline work?
Xanomeline is a selective muscarinic agonist that supports cognitive function in SCZ. It is used in a combination drug that acts at central M1/M4 receptors combined with a peripheral muscarinic antagonist to prevent peripheral side effects. It has shown significant efficacy on the PANSS score in Phase III trials and is approved by the FDA as the first SCZ drug with a new mechanism of action since the 1950s.
43
What is a possible mechanism for how muscarinic agonists like Xanomeline work?
One suggestion is that the drug targets muscarinic receptors located on the presynaptic terminal of DA neurons to negatively regulate the release of DA.
44
What is the "dysconnection hypothesis" of schizophrenia?
The dysconnection hypothesis is a systems-level theory that proposes SCZ is a failure of functional integration. It suggests SCZ arises from disrupted interactions/communication between different cortical regions. This hypothesis aims to unify the observations underlying the Glu and DA hypotheses.
45
What could cause this disrupted connectivity?
This could be due to aberrant development of structural connectivity or impairments in synaptic plasticity altering functional connectivity. Dysconnection could refer to either enhanced (hyperconnectivity) or reduced (hypoconnectivity) connections.
46
How is brain connectivity investigated?
Connectivity can be investigated using imaging techniques such as DTI, PET, fMRI, and MEG/EEG.
47
What do studies show about connectivity in schizophrenia?
Meta-analyses consistently show reduced functional and anatomical connectivity. In particular, reduced fronto-temporal connectivity is observed in both rodents and humans.
48
Is dysconnectivity present only in symptomatic patients?
No, reduced fronto-temporal connectivity is true for at-risk groups and at all stages of the disease. Even individuals at high genetic or ultra-high risk who have not formally shown symptoms display differences in connectivity.
49
How can dysconnectivity be investigated in rodent models?
Forced alternation tasks using a T-maze can be used. In healthy rodents, performing the task involves increased phase coupling (functional connectivity) between the hippocampus and frontal cortex during memory recall. Rodent models of SCZ show significantly decreased task performance and the lack of this specific functional connectivity.
50
How can dysconnectivity be investigated in humans?
Using virtual reality programs to study memory retrieval. Studies comparing SCZ patients and controls during memory retrieval show a huge increase in oscillatory power in the frontal cortex (theta band frequency) in controls, which is much weaker in patients. In controls, strong frontal cortex oscillatory activity is phase-locked/coupled/functionally connected with the hippocampus, but this functional connectivity is not seen in patients during retrieval.
51
How does medication affect functional connectivity in these studies?
The difference in functional connectivity between patients and controls was ONLY seen in unmedicated patients, suggesting medications were somehow rescuing this functional connectivity deficit.
52
How might dysconnectivity explain positive symptoms like hallucinations?
The dysconnectivity hypothesis can explain positive symptoms, suggesting they arise from a failure to integrate a motor efference copy. This means patients are not aware that they are responsible for producing their own actions.
53
What neuroimaging evidence supports the motor efference copy theory?
Studies recording scalp EEG compared patients and controls while listening to someone talk or talking themselves. In controls, when talking, there was a significant increase in functional connectivity between frontal brain regions (generating speech) and the auditory cortex (hearing speech), suggesting the brain tells the auditory cortex the speech is self-generated. In patients who DO exhibit auditory hallucinations, this increase in functional connectivity between frontal regions and the auditory cortex is NOT seen when talking. Patients without auditory hallucinations still showed a difference in connectivity.
54
What are the implications of the dysconnectivity hypothesis?
The hypothesis aims to provide a unifying framework for schizophrenia, integrating different cellular theories and potentially explaining varied responses to medication.
55
Could functional dysconnectivity be a useful biomarker?
Yes, functional dysconnectivity is seen prior to symptom onset, suggesting it may be a useful biomarker to identify individuals at risk and mediate early intervention.
56
Could functional connectivity be a target for novel therapies?
Yes, functional connectivity could potentially be rescued through interventions like brain stimulation or neural implants, rather than solely pharmacological agents.
57
Can connectivity measures predict treatment response?
There is some evidence that measuring functional connectivity can be used to segregate patients based on their likelihood to respond to treatment. Differences in connectivity are seen between patients who respond well, are treatment-resistant, or are ultra-treatment resistant.